The pipeline focuses on novel medicines covering small molecules, monoclonal antibodies, Recombinant proteins, Bi-specific Ab’s, Antibody drug conjugates, Cell therapy, Peptides, Oncolytic viruses and Vaccines.
This report enables Pharmaceutical /Biotech companies, Academic institutes, Individual researchers, Investors, Medical technology companies, Service providers and other associated stake holders to identify and analyze the available licensing/collaborative commercial opportunities in the Immune Checkpoints Drug market.
The report also provides strategic insights on medicines that are likely to have an impact on future Immune Checkpoint treatment space. The report in addition to the monotherapy covers the pipeline for combination therapies associated only with checkpoint agents. In order to effectively deal various diseases, the immune system needs to be able to generate an appropriate counter response.
However, as a part of the natural fail–safe mechanism, to limit overactive immune responses that could lead to an auto-immune disease, there are a number of markers (“immune checkpoint receptors”) found on both tumor cells and antigen presenting cells (dendritic cells, macrophages etc.) that can down-regulate or suppress T cells once the corresponding ligand is bound.
Currently, Researchers are challenged to identify various avenues to prevent T cells from binding these tolerance-inducing ligands either through antibodies or recombinant forms of ligand or receptors. So, these T cells remain active and ready to tackle various diseases. Owing to its high response rate and prolonged overall patient survival the checkpoint therapeutics are gaining in popularity and have shown some impressive results in the areas of Oncology, Inflammation, Respiratory, Autoimmune and Infectious disease.
Since, the approval of BMS ipilimumab (Yervoy) and Merck’s Pembrolizumab (Keytruda) for the treatment of patients with metastatic melanoma, the targeting of immune checkpoints has become the prime focus of several leading academic and industry players. The field of Checkpoint therapy has been successful in attracting some of the biggest pharmaceutical & Biotech companies. These players are forging alliances with several small biotech’s and academic institutes to discover new and more effective ways of exploiting the power of the body’s own immune system in fighting tumors.
Large Pharmaceutical/Biotech companies like AstraZeneca, BMS, Roche, Innate Pharma, Incyte Corporation and MSD are ahead of other companies with their marketed compounds as well as strong pipelines and are considered as leaders in this space. While, companies like Agenus, Compugen, Apogenix, Baxalta, Macrogenics, Adur- Biotech etc., benefit from this race of large pharma/biotechs via asset acquisition, research collaboration or Co-development
- The global Immune Checkpoint therapeutics market is estimated to be $xx billion in 2015 with the approval of new drugs and is expected to grow at a CAGR of high-range double digit from 2016 to 2022 to reach $xx billion by 2022
- Factors contributing to the market growth include, Launch of approved drugs, technological advancements leading to emergence of novel therapeutics & mechanisms, increase in investments, increasing incidence of cancers and low survival rates
- Our analysis indicates that 31.7% of candidates are in Pre-clinical stage followed by xx% in PI clinical
- In addition to small molecules, there is growing interest among researchers on large molecules and novel therapies, such as
-- Monoclonal antibody-based therapy
-- Recombinant proteins
-- Bi-specific Ab’s
-- Antibody drug conjugates
-- Cell therapy
-- Oncolytic viruses
- Emerging role of immunotherapy
- Immune checkpoints
2. Hot Targets
- Immune checkpoints-Types
- Stimulatory checkpoint pathways
- Inhibitory checkpoint pathways
- Targets - Immune checkpoints -Other immune checkpoint targets
- Top companies based on revenue
- Top companies based on Pipeline
3. Market Sizing & Deals Analysis
- Market dynamics
- Market sizing
- Immune checkpoint Deals
4. Pipeline Analysis
- Development stage
- Leading players
- Target analysis
- Therapeutic Segmentation
- Oncology immune checkpoint pipeline by indication
5. Small Molecules
- Competitive landscape MONOCLONAL ANTIBODIES
- Competitive landscape RECOMBINANT FUSION PROTEINS
- Competitive landscape BISPECIFIC ANTIBODIES
- Competitive landscape ANTIBODY DRUG CONJUGATES (ADC's)
- Competitive landscape
- Competitive landscape
7. Major Players
- Company Profiles
- Overview, Pipeline & Deals